Aankondiging • Nov 13
Moss Genomics Inc. announced that it has received CAD 0.1 million in funding Moss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid. Aankondiging • Aug 27
Moss Genomics Inc., Annual General Meeting, Sep 29, 2025 Moss Genomics Inc., Annual General Meeting, Sep 29, 2025. New Risk • May 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding). Aankondiging • Feb 04
Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in funding Moss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Aankondiging • Dec 25
Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in funding Moss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years. Aankondiging • May 31
Moss Genomics Inc., Annual General Meeting, Jul 25, 2024 Moss Genomics Inc., Annual General Meeting, Jul 25, 2024. Board Change • May 09
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 17
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 18
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 30
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 13
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 25
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Sep 21
Moss Genomics Inc. Expects to Launch Its 90-Second Urine Test and Smartphone App in December 2023 Moss Genomics Inc. announced that it expects to launch its 90-second urine test and accompanying smartphone app in December 2023. This revolutionary product is set to transform the way individuals monitor their health and detect potential medical conditions, offering quick, accurate, and convenient results at their fingertips. Moss 90-second urine test utilizes cutting-edge technology to provide rapid and accurate results. By simply collecting a small urine sample, users will receive comprehensive health insights within just 90 seconds. This breakthrough technology eliminates the need for time-consuming laboratory tests. Accompanying the urine test will be a user-friendly smartphone app, providing users with a comprehensive analysis of their health data. Through the app, users will be able to track their health trends, set personalized health goals, and receive real-time notifications and recommendations based on their test results. The app will also offer a secure platform for users to share their data with healthcare professionals, enabling remote monitoring and personalized medical advice. The Moss team, alongside its partners, have worked to ensure the accuracy and reliability of the urine test and app. Extensive testing has been conducted to validate the technology's effectiveness. The results have been overwhelmingly positive, demonstrating the test's ability to detect a wide range of health conditions with high accuracy. The launch of the 90-second urine test and smartphone app is scheduled for December 2023. Board Change • Jul 24
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Jun 17
Moss Genomics Inc. Introduces Diet and Vitamin Reports Moss Genomics Inc. announced the introduction of its diet and vitamin reports which can be ordered directly to your home via its online platform. Up to 80 million genetic variants are analyzed to provide the most insightful information concerning dietary needs and vitamin deficiencies. its diet reports provide information about celiac, alcohol sensitivity, sweet tooth, caffeine related anxiety, hunger, food allergies, response to carbohydrates, bitter taste sensitivity and lactose intolerance. its Reports highlight micronutrient deficiencies and requirements such as Riboflavin, MTHFR (folate), Vitamin B12, Vitamin C, Vitamin D and Iron. These Reports give customers the opportunity to further explore and understand their genetic data. Moss customers can enjoy a comprehensive suite of genetic reports available in its online shop. Moss has created an online healthcare and technology platform integrating labs, services, and products in a shared economy. Moss provides comprehensive and affordable, at-home genetic and microbiome testing paired with personalized wellness reports and offerings to promote total gut, mind, and body health. The Company's services include health reports, personalized food and nutrition recommendations, and a social media platform that allows customers to form communities based on their specific health needs. Board Change • Jun 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 02
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 